< Back to latest news & events

News

Latest CRISPR patent dispute

June 2019

HGF Patent Director and established CRISPR expert Catherine Coombes comments in The Scientist and Science Magazine within hours of recent CRISPR dispute.

The Scientist

USPTO restarts CRISPR Patent dispute between broad and UC

The US patent office declares an interference between the intellectual property held by the Broad Institute and several patent applications filed by the University of California – opposite its previous ruling. The legal battle over the intellectual property surrounding CRISPR gene editing technology is not over. The US Court of Appeals for the Federal Circuit ruled last September that patents held by the Broad Institute of MIT and Harvard University were not in conflict with previously submitted patents from the University of California (UC), Berkeley. But the US Patent and Trade mark Office (USPTO) has now posted documents declaring interference between them—meaning they may cover overlapping IP.

“Certainly, this new patent interference in the US adds to the complexity of the landscape,” Catherine Coombes, a patent director with HGF Limited in the UK who represents CRISPR patent holders in Europe, writes in an email to The Scientist.

Click here for the full article.

Science Magazine

Surprise patent ruling revives high-stakes dispute over the genome editor CRISPR

The high-profile patent fight over who invented a key feature of the genome editor CRISPR has been resurrected. The 3-year-old battle, which a U.S. appeals court appeared to have put to rest in September 2018, pits parties represented by the University of California (UC) against the Broad Institute of Cambridge, Massachusetts. It revolves around the use of CRISPR, originally derived from a DNA-cutting system used by bacteria, in the more complex cells of eukaryotes, which includes humans, making the contested patents key to the potentially lucrative development of novel medicines.

Catherine Coombes, a patent attorney at HGF in York, U.K., who does not represent Broad or UC but is involved in CRISPR patents, says the new interference “adds to the complexity of the landscape.” The European Patent Office has grated “overlapping rights” to both groups and others who have filed CRISPR patent applications, anticipating that legal fights will occur later. “For human therapeutics, it is still too early to know where the key patents will lie,” Coombes says, noting that different enzymes used in various CRISPR systems ultimately may make one invention safer or more effective than another.

Click here for the full article.

Latest updates

PRESS RELEASE - HGF Appoints new Chair of the Board: Formerly Head of Engineering, Lucy Johnson

HGF announced a new Chair to its Management Board, Lucy Johnson. Lucy was previously head of the firm’s Engineering Group.  Effective immediately Lucy succeeds Jason Lumber who held the position …

Read article

Celebrating Success in the Pharmaceuticals Industry: Jazz Pharmaceuticals Enters Deal With Redx

HGF would like to congratulate Redx Pharmaceuticals on their recent deal with Jazz Pharmaceuticals concerning the global rights to Redx’s KRAS Inhibitor Program. This partnership has the potential to provide …

Read article

What's Next for CAR Cell Therapy?

The first generation CAR T cell was discovered in 1993 when the variable region of an antibody was fused to the constant regions of a T cell receptor.  Now, 20 …

Read article

Blog Series: IP Ingredients, Part 7: Data in food and beverage parent applications - Why, What & How much?

Questions I often get asked by innovators looking to file a patent application include: “What kind of experimental data do I need to include?” and “How many examples do we …

Read article

HGF ranked in The Legal 500 Germany 2024

HGF is proud to be ranked in The Legal 500 Germany 2024 guide. The Legal 500 provides the most comprehensive worldwide coverage on recommended Law firms, Lawyers, Attorneys, Advocates, Solicitors, …

Read article

EPO Annual Fee Increases

The European Patent Office (EPO) has announced that revised Official Fees will apply to payments made on or after Monday 1st April 2024. The majority of fees will increase by …

Read article

Tanya Waller Recognised as Lexology Legal Influencer for IP

We are delighted to share that our Trade Mark Director Tanya Waller has been recognised as a Lexology Legal influencer for Q4/2023! Tanya provides high-quality legal content for our website …

Read article